Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal CancerCompleted
NCT04744831Phase 2Updated Jan 14, 2026
Sponsor: Daiichi Sankyo
Advanced Colorectal Cancer
United States, Australia, Belgium, France, Italy +5 more
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort StudyActive Not Recruiting
NCT05089916Phase 2Updated Jan 14, 2026
Sponsor: AIO-Studien-gGmbH
NSCLC · EGFR Positive Non-small Cell Lung Cancer · Oligoprogression
Germany
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled AsthmaCompleted
NCT05251259Phase 2Updated Jan 14, 2026
Sponsor: AstraZeneca
Asthma
United States, Argentina, Australia, Bulgaria, Chile +15 more
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEICompleted
NCT05835778N/AUpdated Jan 14, 2026
Sponsor: AstraZeneca
Biliary Tract Cancer
Japan
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.Completed
NCT06579105Phase 2Updated Jan 13, 2026
Sponsor: AstraZeneca
Diabetes Mellitus, Type 2
United States, Canada, Germany, Hungary, Japan +4 more
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine CarcinosarcomaActive Not Recruiting
NCT03668340Phase 2Updated Jan 12, 2026
Sponsor: Dana-Farber Cancer Institute
Uterine Cancer
United States
Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in SpainCompleted
NCT07013760N/AUpdated Jan 12, 2026
Sponsor: AstraZeneca
Asthma
Spain
Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia PacificCompleted
NCT02442349Phase 2Updated Jan 9, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
Australia, China, South Korea
A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 YearsCompleted
NCT07216131Phase 1Updated Jan 9, 2026
Sponsor: AstraZeneca
Healthy Participants
United States
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of HyperkalaemiaTerminated
NCT05056727Phase 3Updated Jan 8, 2026
Sponsor: AstraZeneca
Renal Insufficiency, Chronic · Hyperkalemia
United States, Argentina, Brazil, Bulgaria, Canada +16 more
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)Completed
NCT05687877N/AUpdated Jan 8, 2026
Sponsor: AstraZeneca
SARS-CoV-2 Infection
Japan
"Breathlessness Diagnostics in a Box" (BiaB) for Primary Care. A Multi-country Quality Improvement Project Using a Randomized Stepped-wedge DesignRecruiting
NCT07320703NAUpdated Jan 7, 2026
Sponsor: General Practitioners Research Institute
Breathlessness · Cardiovascular · Pulmonary · Mental Disease
Netherlands, Portugal, Spain
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisRecruiting
NCT06526104Phase 2Updated Jan 6, 2026
Sponsor: The University of Texas Health Science Center at San Antonio
Hepatocellular Carcinoma · Cirrhosis, Liver
United States
Olaparib In Metastatic Breast CancerActive Not Recruiting
NCT03344965Phase 2Updated Jan 5, 2026
Sponsor: Beth Israel Deaconess Medical Center
Metastatic Breast Cancer · Invasive Breast Cancer · Somatic Mutation Breast Cancer (BRCA1) · Somatic Mutation Breast Cancer (BRCA2)
United States
CARE FOR ALL：an Evaluation of an Asthma QIPCompleted
NCT05440097Phase 4Updated Jan 2, 2026
Sponsor: AstraZeneca
Asthma
China
A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in GreeceCompleted
NCT06185660N/AUpdated Dec 30, 2025
Sponsor: AstraZeneca
Hyperkalaemia
Greece
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive Not Recruiting
NCT02546661Phase 1Updated Dec 29, 2025
Sponsor: AstraZeneca
Muscle Invasive Bladder Cancer
United States, Canada, France, Spain, United Kingdom
The COPD OptimiserCompleted
NCT06659666N/AUpdated Dec 26, 2025
Sponsor: General Practitioners Research Institute
COPD
Netherlands
Effect of Capivasertib on ctDNA in ER Positive Breast CancerWithdrawn
NCT06613516Phase 2Updated Dec 24, 2025
Sponsor: Imperial College London
Breast Cancer · Oestrogen Receptor Positive Breast Cancer
United Kingdom
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction CancerActive Not Recruiting
NCT04592913Phase 3Updated Dec 24, 2025
Sponsor: AstraZeneca
Gastrointestinal Neoplasms · Esophagogastric Junction
United States, Argentina, Belgium, Brazil, Canada +15 more
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular HemolysisRecruiting
NCT06449001Phase 3Updated Dec 23, 2025
Sponsor: Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria · PNH · Extravascular Hemolysis
Canada, France, United Kingdom
Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's LymphomaCompleted
NCT04696692NAUpdated Dec 22, 2025
Sponsor: Institut Claudius Regaud
Diffuse Large B-cell Lymphoma
France
Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlDCompleted
NCT06368427N/AUpdated Dec 22, 2025
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Romania
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCActive Not Recruiting
NCT03997123Phase 3Updated Dec 22, 2025
Sponsor: AstraZeneca
Triple Negative Breast Neoplasms
United States, Argentina, Brazil, Canada, China +25 more
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall RecurrencesTerminated
NCT03955640Phase 1Updated Dec 22, 2025
Sponsor: Thomas Jefferson University
Metastatic Malignant Neoplasm in the Chest Wall · Recurrent Breast Carcinoma
United States

Previous page Next page